Read by QxMD icon Read

Breast cancer AND estrogen

M P Budzik, J Patera, M Sobol, A I Czerw, A Deptała, A M Badowska-Kozakiewicz
INTRODUCTION: Metaplastic breast cancer (MpBC) is a rare but aggressive type of breast cancer accounting for 0.25-1% of all diagnosed invasive breast cancers. Morphologically, it is characterized by differentiation of the neoplastic epithelium into squamous cells and/or mesenchymal-looking tissue. MATERIAL AND METHODS: We analyzed 13 MpBCs selected from the group of 1122 invasive breast cancers. Histopathological examination and analysis of estrogen (ER), progesterone (PR) and HER2 receptors expression in MpBC patients and their comparison to other types of invasive breast cancer has been performed...
December 7, 2018: Breast: Official Journal of the European Society of Mastology
Masayo Hirao-Suzuki, Shuso Takeda, Katsuhiro Okuda, Masufumi Takiguchi, Shin'ichi Yoshihara
Bisphenol A (BPA), recognized as an endocrine disruptor, is thought to exert its activity through a mechanism involving the activation of estrogen receptors (ERα/β). However, a major problem is that very high concentrations of BPA are required (i.e., those in excess of environmental levels) for effective activation of ERα/β-mediated transcriptional activities in vitro, despite the BPA-induced estrogenic effects observed in vivo. To elucidate the causal reasons, we successfully identified a BPA metabolite, 4-methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene (MBP), which exhibits highly potent estrogenic activity both in vivo and in vitro...
December 14, 2018: Molecular Pharmacology
François Le Dily, Enrique Vidal, Yasmina Cuartero, Javier Quilez, A Silvina Nacht, Guillermo P Vicent, José Carbonell-Caballero, Priyanka Sharma, José Luis Villanueva-Cañas, Roberto Ferrari, Lara Isabel De Llobet, Gaetano Verde, Roni H G Wright, Miguel Beato
In breast cancer cells, some topologically associating domains (TADs) behave as hormonal gene regulation units, within which gene transcription is coordinately regulated in response to steroid hormones. Here we further describe that responsive TADs contain 20- to 100-kb-long clusters of intermingled estrogen receptor (ESR1) and progesterone receptor (PGR) binding sites, hereafter called hormone-control regions (HCRs). In T47D cells, we identified more than 200 HCRs, which are frequently bound by unliganded ESR1 and PGR...
December 14, 2018: Genome Research
Yaser Mansoori, Zahra Zendehbad, Alireza Askari, Amin Kouhpayeh, Javad Tavakkoly-Bazzaz, Ziba Nariman-Saleh-Fam, Milad Bastami, Zahra Saadatian, Behnam Mansoori, Amin Yousefvand, Hosein Mansoori, Abdolreza Daraei
Recently, it has been revealed that estrogen-related reproductive factors are linked with some early gene expression lesions associated with malignancy in clinically healthy breasts. Accordingly, the aim of the current study was to evaluate the association of expression levels of estrogen-related long noncoding RNAs (lncRNAs) upstream Eleanor (u-Eleanor) and HOX antisense intergenic RNA (HOTAIR) with the different patterns of reproductive factors in breast tissue of healthy women. The subjects of this study were 98 cancer-free women who had undergone cosmetic mammoplasty...
December 11, 2018: Journal of Cellular Biochemistry
Monika Pizon, Daniel Lux, Ulrich Pachmann, Katharina Pachmann, Dorothea Schott
BACKGROUND: The androgen receptor (AR) is expressed in the majority of breast cancers and across the main breast cancer subtypes. Despite the high frequency of AR expression in breast cancer its appraisal remains controversial because its role is complex, dependent on the hormonal milieu. The aim of the current study was to investigate the frequency of AR and ER positive CETCs in breast cancer patients. METHODS: The number of vital CETCs was determined from blood of 66 patients suffering from breast cancer and the expression of AR and ER on these cells was investigated using the maintrac method...
December 14, 2018: Journal of Translational Medicine
Ana Roguljic, Gulio Spagnoli, Antonio Juretic, Bozena Sarcevic, Marija Banovic, Lidija Beketic Oreskovic
Cancer/testis antigens (CTAs) are a large family of tumor-associated antigens expressed in human tumors of different histological origin, but not in normal tissues, with the exception of the testes and placenta. Numerous immunohistochemical studies have reported associations between CTA expression and a negative estrogen receptor (ER) status in breast tumors, and demonstrated that CTAs are frequently expressed in tumors with higher nuclear grade. The expression of CTAs has not been studied as extensively in ductal carcinoma in situ (DCIS) as it has been in invasive breast cancer...
December 2018: Oncology Letters
Masahiro Shibata, Mitsuro Kanda, Dai Shimizu, Haruyoshi Tanaka, Shinichi Umeda, Takashi Miwa, Masamichi Hayashi, Takahiro Inaishi, Noriyuki Miyajima, Yayoi Adachi, Yuko Takano, Kenichi Nakanishi, Dai Takeuchi, Sumiyo Noda, Yasuhiro Kodera, Toyone Kikumori
Breast cancer (BC) is the most frequently diagnosed malignant tumor in women worldwide, and the development of new molecules associated with BC is essential for the management of this disease. RAS and EF-hand domain-containing ( RASEF ) encodes the GTPase enzyme that belongs to the Rab family. Although the effects of this gene have been reported in several malignant tumor types, the role of RASEF in BC has not been completely elucidated. The aim of the present study was to investigate the importance of RASEF expression in BC...
December 2018: Oncology Letters
Alessio Cortellini, Valentina Cocciolone, Azzurra Irelli, Francesco Pavese, Tina Sidoni, Alessandro Parisi, Paola Lanfiuti Baldi, Olga Venditti, Carla D'Orazio, Pierluigi Bonfili, Pietro Franzese, Luigi Zugaro, Lucilla Verna, Giampiero Porzio, Daniele Santini, Katia Cannita, Corrado Ficorella
The most frequent site of recurrence in breast cancer (BC) is the bone, particularly in patients with 'luminal-like' disease. Denosumab has been shown to prevent aromatase inhibitors (AIs) induced bone resorption in postmenopausal early BC patients and reduce skeletal-related events (SREs) in bone metastatic breast cancer (BMBC). A 'real life' analysis of 90 BMBC patients treated with denosumab was performed. Eighty-six patients (95.6%) had 'luminal-like' disease, 72 (80%) had bone metastases at the time of first recurrence of disease...
December 2018: Oncology Letters
Alicia Romero-Lorca, Maria Gaibar, Angel Luis Armesilla, Ana Fernandez-Santander, Apolonia Novillo
The present study examined the mRNA expression levels of different isoforms of the plasma membrane calcium ATPase 2 (PMCA2) gene generated by alternative splicing at the first intracellular loop (site A) and C-terminal region (site C) in 85 human breast cancer tumor and 69 adjacent non-tumor tissues. Associations were identified between the expression of PMCA2 splice isoforms and the following clinical variables: Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status, tumor size, staging and histological classification, and lymph node status...
December 2018: Oncology Letters
Qiang Lan, Sanam Peyvandi, Nathalie Duffey, Yu-Ting Huang, David Barras, Werner Held, François Richard, Mauro Delorenzi, Christos Sotiriou, Christine Desmedt, Girieca Lorusso, Curzio Rüegg
Neoadjuvant and adjuvant chemotherapies provide survival benefits to breast cancer patients, in particular in estrogen receptor negative (ER- ) cancers, by reducing rates of recurrences. It is assumed that the benefits of (neo)adjuvant chemotherapy are due to the killing of disseminated, residual cancer cells, however, there is no formal evidence for it. Here, we provide experimental evidence that ER- breast cancer cells that survived high-dose Doxorubicin and Methotrexate based chemotherapies elicit a state of immunological dormancy...
December 13, 2018: Oncogene
Luis Molina, Felipe A Bustamante, Kanti D Bhoola, Carlos D Figueroa, Pamela Ehrenfeld
Estrogens generated within endocrine organs and the reproductive system act as ligands for at least three types of estrogen receptors. Estrogen receptors α (ERα) and β (ERβ) belong to the so-called classical family of estrogen receptors, whereas the G protein-coupled receptor GPR30, also known as GPER-1, has been described as a novel estrogen receptor sited in the cell membrane of target cells. Furthermore, these receptors are under stimulation of a family of exogenous estrogens, known as phytoestrogens, which are a diverse group of non-steroidal plant compounds derived from plant food consumed by humans and animals...
December 21, 2018: Clinical Science (1979-)
Carolyn M Klinge
Non-coding RNAs (ncRNAs) are regulators of intracellular and intercellular signaling in breast cancer. ncRNAs modulate intracellular signaling to control diverse cellular processes, including levels and activity of estrogen receptor α (ERα), proliferation, invasion, migration, apoptosis, and stemness. In addition, ncRNAs can be packaged into exosomes to provide intercellular communication by the transmission of microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) to cells locally or systemically. This review provides an overview of the biogenesis and roles of ncRNAs: small nucleolar RNA (snRNA), circular RNAs (circRNAs), PIWI-interacting RNAs (piRNAs), miRNAs, and lncRNAs in breast cancer...
December 12, 2018: Non-Coding RNA
Dan Zhao, Jin-Tang Dong
DRAIC (also known as LOC145837 and RP11-279F6.1 ), is a long non-coding RNA associated with several types of cancer including prostate cancer, lung cancer, and breast cancer. Its expression is elevated in tumor tissues compared to adjacent benign tissues in breast cancer patients and is regulated by estrogen treatment in breast cancer cells. In addition, expression analysis of DRAIC in more than 100 cell lines showed that DRAIC expression is high in luminal and basal subtypes compared to claudin low subtype, suggesting a prognostic value of DRAIC expression in breast cancer...
December 11, 2018: Non-Coding RNA
Dejan Juric, Filip Janku, Jordi Rodón, Howard A Burris, Ingrid A Mayer, Martin Schuler, Ruth Seggewiss-Bernhardt, Marta Gil-Martin, Mark R Middleton, José Baselga, Douglas Bootle, David Demanse, Lars Blumenstein, Karl Schumacher, Alan Huang, Cornelia Quadt, Hope S Rugo
Importance: The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in patients with estrogen receptor-positive (ER+), endocrine therapy-resistant breast cancers. Objective: To assess the maximum tolerated dose (MTD), safety, and activity of alpelisib, an oral, PI3Kα-specific inhibitor, plus fulvestrant in patients with ER+ advanced breast cancer (ABC). Design, Setting, and Participants: An open-label, single-arm, phase 1b study of alpelisib plus fulvestrant was conducted at 10 centers in 5 countries...
December 13, 2018: JAMA Oncology
Mahsa Bagherpour, Kamelia Gharibzad, Hossein Rassi
Breast cancer (BC) is a multistep disease that is thought to result from an interaction between genetic background and environmental factors. In Iran, one of the strongest risk factors for developing BC is a positive family history of the disease. Recently, various polymorphisms of E-cadherin (CDH1) and TERT have been found to be associated with increased BC risk worldwide. This study aimed to analyze the association of CDH1 and TERT single-nucleotide polymorphisms with susceptibility to familial BC (FBC) risk in the Iranian patients...
December 11, 2018: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
Sophie E Mayer, Noel S Weiss, Jessica Chubak, David R Doody, Christopher S Carlson, Karen W Makar, Michelle A Wurscher, Kathleen E Malone
PURPOSE: Tamoxifen is widely used to reduce the risk of breast cancer (BC) recurrence and extend disease-free survival among women with estrogen-sensitive breast cancers. Tamoxifen efficacy is thought to be attributable to its active metabolite, which is formed through a reaction catalyzed by the P450 enzyme, CYP2D6. Inhibition of tamoxifen metabolism as a result of germline genetic variation and/or use of CYP2D6-inhibiting medications ("inhibitors") is hypothesized to increase the risk of adverse BC outcomes among women taking tamoxifen...
December 12, 2018: Cancer Causes & Control: CCC
Abhijith Shettar, Surekha Damineni, Geetashree Mukherjee, Paturu Kondaiah
Gap junction β‑2 gene (GJB2, also known as connexin 26) is a member of the connexin family which forms gap junction channels. Many connexin genes have been considered to be tumor suppressor genes. However, the overexpression of GJB2 has been found to be associated with a poor prognosis in several human cancers. In our previous microarray study, we revealed the overexpression of GJB2 in breast cancer tissues. Hence, in this study, we investigated the expression of GJB2 in human breast cancer and its role in breast cancer cell proliferation and migration...
October 3, 2018: Oncology Reports
Lei Zhu, Xiao-Xia Li, Liang Shi, Jing Wu, Jia-Yi Qian, Tian-Song Xia, Wen-Bin Zhou, Xi Sun, Xu-Jie Zhou, Ji-Fu Wei, Qiang Ding
A total of 70% of breast cancers express the estrogen receptor (ER)α; therefore, targeting the ER may be an effective endocrine therapy with which to inhibit breast cancer growth. Tamoxifen is the most common‑used clinically used drug for the treatment of advanced or metastatic ER‑positive (ER+) breast cancer. However, a substantial proportion of patients become resistant to endocrine therapies. To overcome this limitation, in this stud, we sought to maximize the benefits associated with tamoxifen therapy via drug combination strategies...
November 1, 2018: Oncology Reports
Eric L Bolf, Brian L Sprague, Frances E Carr
Breast and thyroid cancers are two malignancies with highest incidence in women. These cancers often occur metachronously. Women with thyroid cancer are at increased risk for subsequent breast cancer; women with breast cancer have an increased incidence of later development of thyroid cancer suggesting a common etiology. This bidirectional relationship is reported worldwide, however the underlying reasons for this co-occurrence is unknown. In this review, we summarize the current epidemiological evidence and putative mechanisms of these metachronous or synchronous cancers...
December 12, 2018: Cancer Epidemiology, Biomarkers & Prevention
Masataka Sawaki, Tadahiko Shien, Hiroji Iwata
The eighth editions of the primary tumor, lymph node and metastasis classifications for breast cancer issued by the American Joint Commission of Cancer and the Union for International Cancer Control were revised in 2017. The major change made by the American Joint Commission of Cancer is to incorporate biological factors such as estrogen and progesterone receptor, human epidermal growth factor receptor 2, histological grade and multigene prognostic assays, into the staging system. Tumor biomarkers and low recurrence scores confirmed by multigene prognostic assays change the staging...
December 12, 2018: Japanese Journal of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"